The influence of statin use on breast density

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 5, 2006, Pages 1026-1029

  Boudreau, Denise M ^a   Rutter, Carolyn M ^a   Buist, Diana S M ^a  

^a CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; BREAST; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; SCREENING;

ANALYSIS OF VARIANCE; BREAST; CHI-SQUARE DISTRIBUTION; DYSLIPIDEMIAS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAMMOGRAPHY; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 33744779406     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0802     Document Type: Article

References (25)

1. McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 2005;96:60-6E.
2. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10-9.
3. Seeger H, Wallwiener D, Mueck AO. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 2003;111:47-8.
4. Denoyelle C, Albanese P, Uzan G, et al. Molecular mechanism of the anticancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 2003;15:327-38.
5. Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-48.
6. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56:280-5.
7. Cauley JA, Zmuda JM, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 2003;12:749-56.
8. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004;100:2308-16.
9. Yaffe M, Boyd N. Mammographic breast density and cancer risk: the radiological view. Gynecol Endocrinol 2005;21 Suppl 1:6-11.
10. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst 2005;97:368-74.
11. Aiello EJ, Tworoger SS, Yasui Y, et al. Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1411-7.
12. Taplin SH, Mandelson MT, Anderman C, et al. Mammography diffusion and trends in late-stage breast cancer: evaluating outcomes in a population. Cancer Epidemiol Biomarkers Prev 1997;6:625-31.
13. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.
14. Liberman L, Menell JH. Breast imaging reporting and data system (BI-RADS). Radiol Clin North Am 2002;40:409-30.
15. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
16. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Arch Intern Med 1999;130:262-9.
17. Ciatto S, Houssami N, Apruzzese A, et al. Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. Breast 2005;14:269-75.
18. Berg WA, Campassi C, Langenberg P, Sexton NJ. Breast Imaging Reporting and Data System: inter- and intraobserver variability in feature and final assessment. Am J Roentgenol 2000;174:1769-77.
19. Boyd NF, Connelly P, Byng J, et al. Plasma lipids, lipoproteins, and mammographic densities. Cancer Epidemiol Biomarkers Prev 1995;4:727-33.
20. Furberg AS, Jasienska G, Bjurstam N, et al. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 2005;14:33-40.
21. Knight JA, Martin LJ, Greenberg CV, et al. Macronutrient intake and change in mammographic density at menopause: results from a randomized trial. Cancer Epidemiol Biomarkers Prev 1999;8:123-8.
22. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-75.
23. Elmore JG, Carney PA, Abraham LA, et al. The association between obesity and screening mammography accuracy. Arch Intern Med 2004;164:1140-7.
24. Boudreau DM, Doescher MP, Jackson JE, Fishman PA. Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 2004;38:1317-8.
25. Niedhammer I, Bugel I, Bonenfant S, et al. Validity of self-reported weight and height in the French GAZEL cohort. Int J Obes Relat Metab Disord 2000;24(9):1111-8.